1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd.

WUXAY
WuXi AppTec Co., Ltd.US flagOther OTC
25.43
USD
+0.48
- -
77.19BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.95
2.32
2.88
3.52
4.03
4.69
5.92
7.86
13.44
13.73
13.62
15.9
14.18
Basic EPS, GAAP
0.22
0.17
0.46
0.56
0.95
0.68
1.06
1.75
3.01
3.27
3.28
6.7
6.21
Free Cash Flow per Basic Share
-0.3
-0.09
0.38
0.2
-0.25
0.14
0.34
-0.81
0.22
2.68
2.92
4.08
-1.69
Dividend per Share
0.01
0.02
0.02
0.02
0.03
0.27
0.23
0.31
0.55
0.94
1.07
1.74
1.63
Book Value per Share
1.18
1.53
2.52
2.96
6.45
6.24
11.09
13.02
15.74
18.57
20.3
26.72
27.93
Tangible Book Value per Share
1.03
1.27
2.24
2.33
5.8
5.42
10.27
11.83
14.52
17.33
19.42
26
27.23
Basic Weighted Avg Shares
2,128
2,105
2,123
2,203
2,388
2,747
2,793
2,913
2,928
2,938
2,881
2,858
2,925
Sales/Revenue/Turnover
4,140
4,883
6,116
7,765
9,614
12,872
16,535
22,902
39,355
40,341
39,241
45,456
41,497
Operating Margin (%)
16.73
10.36
20.27
22.71
20.45
20.36
20.16
20.35
24.77
29.17
29.59
37.41
43.33
Depreciation Expense
- -
327
345
403
544
841
1,003
1,286
1,693
2,284
2,782
3,474
- -
Net Income, GAAP
462
349
975
1,227
2,261
1,855
2,960
5,097
8,814
9,607
9,450
19,151
18,155
Effective Tax Rate (%)
16.58
14.67
18.9
18.58
9.58
18.21
11.37
14.62
16.16
18.02
17.09
19.13
18.46
Profit Margin (%)
11.15
7.15
15.94
15.8
23.51
14.41
17.9
22.26
22.4
23.81
24.08
42.13
43.75
Working Capital
2,345
3,365
1,839
845
7,883
6,029
15,139
9,001
9,498
15,666
22,464
42,442
44,353
LT Debt
87
- -
- -
300
644
3,742
2,886
1,626
1,765
1,786
3,506
2,274
2,190
Total Equity
4,903
6,430
6,062
6,927
18,136
17,410
32,718
38,757
46,927
55,517
59,086
80,248
83,884
Return on Invested Capital (%)
- -
6.69
14.47
18.03
12.57
10.02
9.75
9.85
16.85
16.66
15.15
17.66
17.91
Return on Capital (%)
- -
0.6
12.81
15.84
16.3
8.97
10.34
12.91
18.49
16.96
15.25
25.16
22.77
Return on Common Equity (%)
- -
11.69
21.82
20.28
18.69
10.61
11.89
14.36
20.72
18.89
16.62
27.69
25.35

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6,146
6,142
6,337
LT Borrowings
1,819
1,819
1,799
LT Finance Leases
455
418
391
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,984
2,984
2,984
Market Capitalization
263,187
312,931
399,780

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
61,677
65,169
73,147
Cash, Cash Equivalents & STI
40,938
43,384
46,640
Accounts Receivable, Net
7,263
7,701
10,472
Inventories
8,993
9,966
11,127
Total Current Liabilities
19,235
19,041
28,795
Payables & Accruals
- -
- -
- -
ST Debt
6,146
6,142
6,337
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
35.44%
20.02%
35.82%
Free Cash Flow
-14.63%
135.82%
38.82%
Net Income, GAAP
58.63%
51.02%
102.65%
Sales/Revenue/Turnover
26.43%
25.19%
15.84%
Total Cash Common Dividend
115.4%
52.71%
61.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,982
9,259
10,461
11,539
39,241
2025
9,655
11,145
- -
12,599
45,456
2026
12,436
16,462
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.67
- -
- -
- -
3.28
2025
1.29
- -
- -
- -
6.7
2026
1.59
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
1.07
2025
0.02
- -
- -
- -
1.74
2026
0.01
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ge Li
Full Time Employees
33,834
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
288 Fute Zhong Road Shanghai SH People's Republic of China 200131
IPO Date
Feb 24, 2021
Website
wuxiapptec.com
Similar Companies
Thermo Fisher Scientific Inc. (TMO)
Natera, Inc. (NTRA)
PerkinElmer, Inc. (PKI)
DermTech, Inc. (DMTKQ)
Danaher Corporation (DHR)
hVIVO plc (HVO.L)
Business
WuXi AppTec Co., Ltd. (WUXAY) operates as a global contract research, development and manufacturing organization (CRDMO) that provides end-to-end pharmaceutical services from drug discovery to commercial manufacturing for the pharmaceutical, biotech and medical device industries worldwide. Founded in 2000 and headquartered in Shanghai, China, the company delivers integrated solutions across Asia, Europe and North America, including WuXi Biology for target discovery to candidate selection in small molecules, peptides, oligonucleotides and biologics; WuXi Chemistry for small molecule CRDMO encompassing discovery, process development, formulation and custom manufacturing; TIDES CRDMO for oligonucleotides and peptides across the supply chain; and Laboratory Testing for DMPK, safety assessments and bioanalytical support in modalities such as PROTACs, ADCs and emerging therapies; with additional capabilities in preclinical testing services. The company serves nearly 6,000 customers in over 30 countries, focusing on small molecules, biologics and cell and gene therapies to accelerate healthcare innovation. In recent developments, WuXi AppTec agrees to sell its U.S. and U.K. Advanced Therapies cell therapy unit to Altaris, LLC, with the transaction expected to close in the first half of 2025 to sharpen focus on its core CRDMO platform; signs a definitive agreement in October 2025 with Hillhouse Investment Management to divest its China-based clinical research services, including WuXi Clinical CRO and WuXi MedKey SMO, pending regulatory approvals; completes a second RMB1.0 billion A-share repurchase program in August 2025, cancelling all repurchased shares; and raises HK$7.70 billion through a share placement earlier in 2025 to support global expansion amid strong revenue growth, with H1 2025 continuing operations revenue up 24.2% year-over-year.

Company News

Company News APIChatGPT

  • defenseworld.net

    WuXi AppTec (OTCMKTS:WUXAY) Sees Unusually-High Trading Volume – Time to Buy?

  • prnewswire.com

    WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability

  • zacks.com

    Recent Price Trend in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) is Your Friend, Here's Why

  • prnewswire.com

    WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion

  • zacks.com

    Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why

  • zacks.com

    Here's Why Momentum in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Should Keep going

  • reuters.com

    WuXi AppTec files complaint against U.S. DoD for linking it to Chinese military

  • prnewswire.com

    WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index

  • defenseworld.net

    Short Interest in WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY) Increases By 76.7%

  • seekingalpha.com

    WuXi AppTec Co., Ltd. (WUXAY) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY) Short Interest Update

  • seekingalpha.com

    WuXi AppTec Co., Ltd. (WUXAY) Presents at 44th Annual J.P.

  • defenseworld.net

    WuXi AppTec (OTCMKTS:WUXAY) Shares Down 1.4% – What’s Next?

  • prnewswire.com

    WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry

  • benzinga.com

    China's Corporate Pivots: Alibaba's Food Delivery Gambit and WuXi AppTec's Geopolitical Hedge

  • prnewswire.com

    WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends

  • prnewswire.com

    WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled

  • prnewswire.com

    WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year

  • reuters.com

    China's Wuxi Apptec to raise over $980 million to boost expansion

  • seekingalpha.com

    WuXi AppTec Co., Ltd. (WUXIF) Q2 2025 Earnings Call Transcript